The mitogen-activated protein kinase (MAPK) pathway is one of the most well characterized pathways in cancer biology.  Hyperactivation of this complex signalling cascade is frequently associated with oncogenesis and tumor progression. This presentation will detail some highlights from our work at Novartis to drug the ERK and RAF nodes of the MAP kinase pathway, work that has lead to development of ERK2 inhibtior clinical candidate LTT462 and an advanced and well-characterized cRAF inhibitor compound 1.

Drugging ERK and RAF nodes of MAP kinase pathway

ACS Spring 2022

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.